氘可来昔替尼(Deucravacitinib) - 药物靶点：TYK2_在研适应症：红皮病性银屑病，寻常性银屑病，脓疱型银屑病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Deucravacitinib (USAN)、德卡伐替尼、BMS-986165

+ [5]

靶点

TYK2

作用方式

抑制剂

作用机制

TYK2抑制剂(酪氨酸蛋白激酶TYK2抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病感染+ [3]

在研适应症

红皮病性银屑病寻常性银屑病脓疱型银屑病+ [9]

非在研适应症

斑秃溃疡性结肠炎克罗恩病+ [11]

原研机构

Bristol Myers Squibb Co.

在研机构

Bristol-Myers Squibb Pharma EEIG

Bristol Myers Squibb Co.Bristol-Myers Squibb Australia Pty Ltd.

+ [2]

非在研机构

百时美施贵宝（中国）投资有限公司

Dartmouth-Hitchcock Medical Center

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2022-09-09),

斑块状银屑病

最高研发阶段(中国)批准上市

特殊审评特殊审批 (中国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C20H22N8O3

InChIKeyBZZKEPGENYLQSC-FIBGUPNXSA-N

CAS号1609392-27-9

关联

94

项与氘可来昔替尼相关的临床试验

NCT07280702

/ Not yet recruiting临床4期IIT

Deucravacitinib-TNF Combination Therapy for Difficult-to-Control Psoriatic Disease

The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life.
This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.

开始日期2025-12-15

申办/合作机构

The University of Texas Southwestern Medical Center

NCT06979453

/ Recruiting临床3期

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

开始日期2025-12-03

申办/合作机构

Bristol Myers Squibb Co.

NCT07012057

/ Withdrawn临床2期IIT

A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis

Background:
Dermatomyositis (DM) and juvenile dermatomyositis (JDM) are diseases that weaken the immune system. DM and JDM can affect the muscles, skin, joints, and lungs and cause skin rashes and muscle inflammation. Symptoms include weakness, pain, fatigue, and rash. Not everyone responds to current treatments. The FDA has approved a drug called deucravacitinib to treat people with plaque psoriasis. Researchers want to find out if this drug can help people with DM or JDM, too.
Objective:
To test deucravacitinib in people with DM or JDM.
Eligibility:
People aged 18 years and older with DM or JDM.
Design:
Participants will have 9 clinic visits over 28 weeks.
Participants will be screened. They will have a physical exam with blood and urine tests. They will have a test of their heart function. They will complete a short questionnaire about their daily life, pain level, and ability to walk, eat, and do other activities.
Deucravacitinib is a pill taken by mouth twice per day at home. Participants will come to the clinic once every 4 weeks for 24 weeks while they are taking the drug. They will have a final visit 4 weeks after their last dose of the study drug. Blood and urine tests will be repeated during these visits. Each visit may take up to 6 hours.
If the drug is helping them, participants may extend their treatment beyond the first 24 weeks. Then they will visit the clinic every 3 months.

开始日期2025-11-21

申办/合作机构-

100 项与氘可来昔替尼相关的临床结果

登录后查看更多信息

100 项与氘可来昔替尼相关的转化医学

登录后查看更多信息

100 项与氘可来昔替尼相关的专利（医药）

登录后查看更多信息

296

项与氘可来昔替尼相关的文献（医药）

2026-01-01·CORNEA

Conversion of Conjunctival Nevus to Melanoma in a Patient Taking the TYK2 Inhibitor Deucravacitinib

Article

作者: Whitcomb, Nicholas ; Lee, Hyunjoo J.

Purpose::

To describe a case of a patient with a preexisting conjunctival nevus giving rise to conjunctival melanoma as a potential adverse effect of the new selective Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitor deucravacitinib.

Methods::

Single case report.

Results::

A 50-year-old woman with a medical history of psoriasis, for which she was 6 months into treatment with deucravacitinib, presented with 3 months of progressive enlargement and darkening of a brown-pigmented lesion in the left eye. This lesion evolved in the place of a pigmented nodule in the left eye that had been present and unchanging for at least several years prior. Urgent surgical excision, cryotherapy, and ocular surface reconstruction were performed without complication. Biopsy of the lesion confirmed the presence of a conjunctival melanoma, invasive to a depth of 0.7 mm, arising from a precursor conjunctival nevus. The patient was subsequently referred to an oncologist, who recommended discontinuing deucravacitinib.

Conclusions::

Deucravacitinib-mediated inhibition of tyrosine kinase 2 (TYK-2) disrupts signaling of cytokines interferon alpha (IFN-α), interleukin (IL)-12 and IL-23, providing a theoretical mechanism for increased risk of malignancy while taking the drug. In this case, the temporal relation between starting deucravacitinib treatment and the rapid growth of a conjunctival melanoma arising from a nevus is concerning for a protumor effect of this immunomodulatory drug. Patients with ocular lesions at risk of malignant transformation should perhaps be closely monitored while on deucravacitinib therapy until more is known regarding the degree of risk of malignant transformation because of immunomodulation from TYK2 inhibition.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan

Article

作者: van de Wetering, Gijs ; Tada, Yayoi ; Roberts, David ; Hikichi, Yusuke ; Kim, Hyunchung ; Smith, Martina

OBJECTIVE:

This study aimed to evaluate the cost-effectiveness of deucravacitinib vs. apremilast as a treatment for moderate-to-severe psoriasis patients from a Japan healthcare system perspective.

METHODS:

A Markov sequence model was developed, consisting of an induction phase, maintenance phase, best supportive care and death. Clinical inputs were predominantly derived from the POETYK-PSO-1 and -2 trials (NCT03624127 and NCT03611751), and cost and resource use inputs were derived from several Japanese sources, including Ministry of Health and Welfare (MHLW) data and the outputs of a Delphi survey with Japanese clinical experts. Health-related quality of life inputs were based on the change in utility associated with different levels of Psoriasis Area and Severity Index (PASI) response. Deterministic and probabilistic sensitivity analyses were conducted to account for uncertainty around the base case and several scenario analyses were performed to explore structural uncertainty related to assumptions and methodological choices.

RESULTS:

In the base case, treatment with deucravacitinib results in a discounted QALY gain of 0.30 and discounted incremental costs of ¥459,771 compared to apremilast, resulting in an ICUR of ¥1,546,713 per QALY which is below the Japanese willingness to pay threshold of ¥5,000,000 per QALY. Deterministic and probabilistic sensitivity analyses support the results of the base case. The latter shows that deucravacitinib has a 97.8% probability of being cost-effective compared to apremilast at the ¥5,000,000 per QALY threshold. The outcomes of all scenarios confirmed the cost-effectiveness of deucravacitinib compared to apremilast, with deucravacitinib being dominant in one scenario.

CONCLUSIONS:

Deucravacitinib is cost-effective compared to apremilast in patients with moderate-to-severe plaque psoriasis in Japan, primarily driven by improvements in health-related quality of life associated with a more favorable PASI response. This conclusion is supported by extensive sensitivity and scenario analyses.

2025-12-31·ANNALS OF MEDICINE

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis

Review

作者: Wang, Bangmao ; Yang, Huibin ; Zhang, Qingyu ; Zhao, Yuxuan ; An, Ting ; Shi, Xiaojing

BACKGROUND AND OBJECTIVE:

Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.

PATIENTS AND METHODS:

Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions.

RESULTS:

A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (versus placebo) showed a trend towards increased risks of VTE (OR=1.36, 95% CI: 0.23-8.03) and CVE (OR=1.08, 95% CI: 0.24-4.85), and ranked higher than placebo for the risk of VTE [P-score=0.766 (versus 0.722)]. Notably, Deucravacitinib ranked lowest for all cardiovascular risks, and significantly decreased the risks of VTE (OR=0.03, 95% CI: 0.00-0.87) and CVE (OR=0.03, 95% CI: 0.00-0.87) compared with placebo.

CONCLUSIONS:

Although a trend of increased cardiovascular risks was found considering dose, no significantly increased cardiovascular risk was associated with JAKinibs in IBD patients, and Deucravacitinib significantly decreased the risks of VTE and CVE.

604

项与氘可来昔替尼相关的新闻（医药）

2025-12-23

·精准药物

盘点2024年度潜在成药分子

早研早知道近期（Dec. 11），来自 Durg Hunter 的 Dennis Koester 快评了 2024年10款年度分子，并重点介绍了候选中出现的主要趋势和科学突破。文末点击“阅读原文”看原视频，部分信息来自于摩熵医药数据库检索补充。 EARLY R&D TALKING 过去四年 TOP1 分子回顾 01 （1）2020年，Lenacapavir 来自美国吉利德科学公司，针对 HIV p24 衣壳蛋白；这是一种改变 HIV 治疗格局的分子，在2020年度 Drug Hunter 举行的年度分子评选中，脱颖而出，被评为 TOP 1 年度分子。两年后，2022年12月，该药物首次获得 FDA 批准！用于抗感染领域，治疗HIV-1型感染。作为I 型新分子实体，用于与其它抗逆转录病毒药物联合使用，适用于治疗多重耐药 HIV-1 感染且耐药、不耐受或安全性考虑而对当前尼康转录病毒治疗方案无应答的治疗经验丰富的成人患者。（2）2021年，Nirmatrelvir 来自美国辉瑞，针对 SARS-Co 3CLpro；一种对抗 COVID-19 的可逆共价 Mpro 抑制剂。这款要求在加速药物研发方面有太多值得吸取的经验教训。2021年，获评为 TOP1 分子。两年后，2023年5月，该药物首次获得 FDA 批准，用于抗感染领域，治疗 COVID-19。（3）2022年，Deucravacitinib 来自百时美施贵宝（BMS），针对酪氨酸激酶2（TYK2）；一种基于表型筛选发现的激酶抑制剂；其之所有引入瞩目，是因为两个不常见：首先，这是一种激酶抑制剂（常见于肿瘤治疗），并不常见免疫领域疾病。此外，这类激酶抑制剂一般也多基于结构的药物发现，在表型筛选中发现也并不常见。此外，这也是首个从头发现的氘代药物。而且，它相对于其它 JAK 激酶具有选择性。 2022年 9月，该药物获得 FDA 批准，用于免疫系统银屑病的治疗。（4）2023年，Enlicitide （MK-0616）来自默沙东的，针对 PCSK9；一种口服大环肽，源于 mRNA 环肽展示，并经过SBDD优化改善，用于心血管系统，动脉粥样硬化的治疗。目前，已有多项 III 期临床达到预期，有望不久的将来获批。 EARLY R&D TALKING 10款年度分子候选 02 2.1 Laroprovstat 靶点：PCSK9 Laroprovstat（AZD0780）是由阿斯利康和Dogama制药开发的，首个用于临床靶向 PCSK9 非肽类小分子口服抑制剂。该化合物最初是由基于片段的筛选，发现靶向全长人PCSK9的C末端结构域结合倾向的片段，再经由基于结构配体扩展，优化了其结合亲和力；随后经由代谢稳定性、安全性改善等发展而出的最终分子。 2.2 Icotrokinra 靶点：IL23R Icotrokinra（JNJ-2113）是由强生和Protagonist 开发的口服大环肽 IL-23R 调节剂。其先导化合物是由噬菌体展示发现，进而经过结构优化发展而来。目前该药物三期临床表现理性，有望获批上市。在免疫调剂治疗领域，用于治疗12岁及以上成人和儿童中度至重度斑块状银屑病。 2.3 Suzetrigine 靶点：NaV1.8 Suzetrigine（VX-548）是一种由美国福泰制药公司研发的口服、变构钠离子通道抑制剂；2025年1月获FDA批准用于治疗急性疼痛。这是20年来首款钠离子通道新型药物，此前的抑制剂研发一度让人失望，如下，或是因为药代动力学问题或II期结果无效而终止。而 VX-548 从研发到 FDA获批，经历了一个漫长的过程。 2.4 Hro761 靶点：WRN Hro761 是诺华研发的一款WRN解旋酶口服、变构抑制剂，可诱导 WRN降解。目前在 I 期临床研究中。该药物的发现经历了一系列“变色龙式的转变”，同时优化分子的溶解性与渗透性。 2.5 VVD-214 靶点：WRN VVD-214 是由 Vividion 制药开发的一款 WRN 解旋酶口服、变构、不可逆共价抑制剂，可诱导 WRN降解。这款药物是由 Vividion 的蛋白组学筛选平台，利用带亲电弹头的小分子化合物直接筛选发现。其中，若反应性弹头在选择性中起到关键作用。现由罗氏推进到临床I期。 2.6 Zoldonrasib 靶点：KRAS(G12D)(on) Zoldonrasib（RMC-9805）是一款由 Revolution Medicines 开发的KRAS(G12D)(ON）口服、共价抑制剂；其开发与发展利用了基于 CypA 的分子胶机制。目前正在临床I/II期研究。 2.7 Daraxonrasib 靶点：pan-RAS Daraxonrasib（RMC-6236）是Revolution Medicines 利用基于 CypA分子胶机制开发的另一款重磅药物，这是一款泛-RAS 抑制剂，对 KRAS(G12V)、G13X、Q61X均有活性。目前已推进到临床 III 期。 2.8 Inavolisib 靶点：PI3Kα Inavolisib是由基因泰克意外发现的一种靶向 PI3Kα 突变体的选择性单分子降解剂。其突破性疗法获得美国 FDA 2024年10 批准，用于治疗 HR+/HER2-乳腺癌。其意外发现是在对 Taselisib 的机制分析中发现的。 2.9 KT-474 靶点：IRAK4 KT-474 是由Kymera制药开发的一种 IRAK4 口服、选择性降解剂。 2.10 Bexobrutideg 靶点：BTK Bexobrutdeg(NX-5948）是由 Nurix 制药开发的一款靶向 BTK 的口服、CNS活性降解剂。目前在临床Ia/Ib。声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

2025-12-22

·药研苑

武田TYK2抑制剂Zasocitinib银屑病3期试验取得积极结果

“药品营销避坑”试读：药品导入期管理视频课（试听）药品生命周期管理（案例）药品立项需要注意什么（案例） 2025年12月18日，武田制药Takeda宣布Zasocitinib在两项关键性3期、随机、多中心、双盲、安慰剂与活性对照研究中取得积极结果。早在第 4 周即可观察到显著更高的银屑病面积及严重程度指数（PASI）较基线改善至少75%的参与者比例显著高于安慰剂，并持续至第24周。至第16周，达到静态临床医生整体评估（sPGA）评分为0或1的参与者比例均优于安慰剂，超过一半的受试者达到皮损清除或几乎清除（PASI 90），约30%的受试者达到皮损完全清除（PASI 100），并且应答率持续至第24周。在安全性方面，Zasocitinib总体耐受性良好，安全性与既往研究一致，最常见的不良事件包括上呼吸道感染，鼻咽炎和痤疮，未观察到新的安全性信号。 Zasocitinib（TAK-279）为选择性口服TYK2抑制剂，对于TYK2抑制作用远高于其他JAK，并且单次绘药对于TYK2的抑制作用超过24小时（Shailly Mehrotra., 2026）。选择性TYK2抑制，与非选择性JAK抑制剂相比，涉及的细胞因子较少，不良反应更少。目前在国内获批JAK抑制剂包括乌帕替尼（Upadacitinib）、芦可替尼（Ruxolitinib）、托法替布（Tofacitinib）、阿布昔替尼（Abrocitinib）、巴瑞替尼（Baricitinib）、戈利昔替尼（Golidocitinib）、氘可来昔替尼（Deucravacitinib）、利特昔替尼（Ritlecitinib）、艾玛昔替尼（Ivarmacitinib）和吉卡昔替尼（Gecacitinib）。其中氘可来昔替尼为选择性TYK2抑制剂。相关阅读：礼来口服小分子Orforglipron可用于司美格鲁肽减重序贯治疗一年两次，FDA批准德莫奇单抗用于重度哮喘 FDA批准德曲妥珠单抗一线治疗HER2阳性转移性乳腺癌 FDA批准埃万妥珠单抗/透明质酸酶皮下注射固定组合诺诚健华第二代TRK抑制剂佐来曲替尼国内获批诺诚健华奥布替尼系统性红斑狼疮2b期研究达到主要终点圣因生物减肥肉，不减瘦肉siRNA候选药物SGB-7342获批临床健康元流感新药玛帕西沙韦国内获批赛诺菲肌球蛋白抑制剂阿夫凯泰国内获批用于肥厚型心肌病免疫检查点抑制剂，谁将成为下一个王者？质子泵相关抑酸类药物市场即将回暖改剂型，口服液体制剂“金矿”还是“陷阱” 生物仿制药不再要求必须开展临床试验，FDA发布新指导原则草案中药1类新药距离封神还有多远药品导入期管理视频课相关内容只作为药物研发的参信息。不构成任何与用药咨询有关的建议。如需发稿，您可通过在药研苑公众号下以发送信息的方式将官网或官方公众号的稿件链接和标题发送给我们。我们将择优确定是否发布。

临床3期临床结果临床2期上市批准

2025-12-22

·仲哥治银

牛皮癣中重度患者别再等了：2025年国产新药爱达罗上市，皮肤干净不是梦？

你有没有过这样的日子：胳膊腿上那些红斑鳞屑怎么遮都遮不住，夏天不敢穿短袖，晚上痒得翻来覆去睡不着？很多人跟我聊过，说自己得牛皮癣好几年了，涂药膏、吃中药、打生物针都试过，好一阵坏一阵，钱花了不少，心累更不少。尤其是中重度那种，皮损一大片，关节还隐隐疼，工作生活都受影响，感觉这病就像甩不掉的影子。我认识一个患者，老李，五十多岁，牛皮癣十几年了。以前用进口生物制剂，效果是好，就是贵，坚持下来难。去年听说有新药，他去医院咨询了下，现在用着国产的爱达罗®（依若奇单抗），几个月下来，皮肤明显干净多了，人也精神了。他说，终于敢跟老朋友聚会，不用总藏着胳膊了。 2025年4月，康方生物的爱达罗正式上市，这是中国首个自主创新的IL-12/IL-23双靶向单抗。临床数据里，很多中重度患者用后皮损改善很快，PASI 75（改善75%）比例高，生活质量上去了。比起以前单靶点的药，它同时堵住两个关键炎症路径，效果更稳。当然，牛皮癣这病慢性，得长期管。但现在选择多了，国产新药可及性更好，将来价格或许更亲民。很多人反馈，用上合适方案后，自信心回来了，敢计划旅行、换工作了。如果你也正纠结中重度牛皮癣怎么控，别一个人扛着。去正规医院皮肤科聊聊，这些新药也许就是你的机会。早点行动，早点轻松点。牛皮癣治疗迎来国产创新药时代：聚焦2025年新上市的爱达罗等重磅选项牛皮癣，学名叫银屑病，国内患者超700万，中重度占了不少。这病不光皮肤红斑鳞屑反复，还可能带关节痛、心理负担。很多人折腾多年，从外用激素到口服药，再到生物制剂，效果有，但总有不满意的地方。好消息是，2025年治疗格局又变了。康方生物的**爱达罗®（依若奇单抗注射液）**在4月获批上市，这是中国首个且唯一的IL-12/IL-23双靶向创新单抗。之前2024年还有金立希、安达静这些国产IL-17抑制剂上市，加上颂狄多这种口服小分子，患者选择丰富多了。爱达罗为什么值得关注？爱达罗靶向IL-12和IL-23这两个共享p40亚基的细胞因子，从源头阻断炎症。临床试验显示，中重度斑块状银屑病患者用后，皮损清除率高，起效稳，安全性数据也靠谱。最常见不良反应轻微，像上呼吸道感染啥的。它不是孤军作战。2024年智翔金泰的金立希（赛立奇单抗）和恒瑞的安达静（夫那奇珠单抗）也上市了，都是国产IL-17A抑制剂，快速起效，很多患者几周就见改善。口服选项也有突破。颂狄多（氘可来昔替尼）是全球首款TYK2变构抑制剂，已进医保，每天一片，方便长期管。这些新药怎么选？得看个人情况。医生会评估皮损面积、严重度、有没有关节炎等。注射生物制剂：像爱达罗、金立希、安达静，适合中重度顽固型，清除率高。口服小分子：颂狄多，不想打针的首选，疗效持久。传统方案：轻度外用+光疗，中度加口服免疫抑制。药物类型代表药主要特点适合人群 IL-12/IL-23双靶向爱达罗（依若奇单抗）国产创新，双阻断，疗效稳中重度，追求长期控制 IL-17A抑制剂金立希、安达静国产，起效快，清除率高中重度顽固皮损 TYK2抑制剂颂狄多（氘可来昔替尼）口服，便捷，已进医保不愿注射，需长期管理 IL-23抑制剂古塞奇尤单抗等注射间隔长中重度，伴系统症状用药小提醒新药好，但不是万能。得医生指导，用前筛查感染，用中定期查血。生活上，控体重、别熬夜、心情放松，这些都帮大忙。我见过不少患者，用上这些新方案后，说最多的话是：“皮肤终于正常了。”牛皮癣虽慢性，但现在真可控。别拖，有症状早咨询，说不定下一个自信满满的人就是你。想了解爱达罗、金立希或其他新药详情，建议去医院皮肤科问问专业医生，或关注正规信息渠道。规范治疗，日子会好起来。

上市批准孤儿药临床研究

100 项与氘可来昔替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11817	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
红皮病性银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
寻常性银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
脓疱型银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
斑块状银屑病	美国	Bristol Myers Squibb Co.	2022-09-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	申请上市	美国	Bristol Myers Squibb Co.	2025-07-21
幼年特发性关节炎	临床3期	美国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	中国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	巴西	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	保加利亚	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	捷克	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	德国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	意大利	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	罗马尼亚	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	西班牙	Bristol Myers Squibb Co.	2025-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05710185 (CTgov)	临床4期	手掌和足底脓疱病	3	Deucravacitinib	願網願顧壓製積衊積蓋 = 艱願衊憲蓋築醖鬱夢膚範選艱蓋淵鏇衊網製衊 (艱鹽鏇餘壓遞餘鹽繭製, 網觸壓齋鑰鏇齋蓋獵觸 ~ 獵糧鹹積餘鹹齋願積淵) 更多	-	2025-12-16
NCT03624127 \| NCT03611751 (POETYK PSO-2, Pubmed \| Dermatol Ther (Heidelb))	临床3期	斑块状银屑病	422	Placebo	廠簾築窪鹽獵顧夢觸淵(範窪窪鹽積構廠艱齋鬱) = 蓋觸餘網餘觸壓簾顧願願廠網選襯鑰蓋範膚獵 (鑰網繭顧餘襯遞範鑰鬱 )	积极	2025-12-05
				Deucravacitinib 6 mg once daily	廠簾築窪鹽獵顧夢觸淵(鑰繭鹹齋鹽獵顧壓簾廠) = 醖齋窪網壓構壓構積範遞觸鹹繭衊繭觸壓顧夢 (淵夢願憲蓋襯網構夢鏇 ) 更多
NCT06476834 (CTgov)	临床4期	-	8	Deucravacitinib	遞範選窪網願簾遞鑰襯(顧衊壓構糧窪鹹鹹願廠) = 膚簾憲範鏇製鹹願憲鹽憲願願艱齋糧壓構製遞 (壓觸鬱窪艱齋壓艱糧觸, 59.5) 更多	-	2025-12-03
NCT04908202 (POETYK PsA-1, ACR2025)	临床3期	银屑病关节炎	1,294	Deucravacitinib 6 mg	衊餘廠遞遞構觸壓鑰網(憲簾壓淵獵繭鑰鹽窪顧) = 簾膚選顧糧積鑰艱觸選壓鹽淵艱顧簾構鹹網鬱 (選繭艱顧膚廠壓鑰積鏇 ) 更多	积极	2025-10-24
				Placebo	衊餘廠遞遞構觸壓鑰網(憲簾壓淵獵繭鑰鹽窪顧) = 網齋糧齋顧觸憲鏇獵簾壓鹽淵艱顧簾構鹹網鬱 (選繭艱顧膚廠壓鑰積鏇 ) 更多
NCT04857034 (PAISLEY DLE/SCLE, ACR2025)	临床2期	皮肤红斑狼疮	32	Deucravacitinib 3 mg BID	構夢選繭醖餘衊願獵襯(遞糧齋願夢積製鏇鑰襯) = 網繭積膚齋鏇淵壓廠選顧鹹遞齋蓋憲獵窪蓋醖 (淵餘窪鬱簾夢觸遞鹽積 ) 更多	积极	2025-10-24
NCT04857034 (PAISLEY CLE, ACR2025)	临床2期	皮肤红斑狼疮 IFN-5 \| IFN-γ \| inflammation	78	Deucravacitinib 3 mg twice daily	鹹鬱選齋積簾齋壓簾鹹(夢簾夢鏇壓壓網觸簾襯) = 壓範衊壓窪構醖窪膚範鹹選糧餘衊獵醖範窪膚 (鑰簾遞繭鬱獵遞鏇襯蓋 )	积极	2025-10-24
				Deucravacitinib 6 mg twice daily	鹹鬱選齋積簾齋壓簾鹹(夢簾夢鏇壓壓網觸簾襯) = 襯鹽鹹鹹鹹觸築遞選鏇鹹選糧餘衊獵醖範窪膚 (鑰簾遞繭鬱獵遞鏇襯蓋 )
NCT03252587 (PAISLEY SLE, ACR2025)	临床2期	系统性红斑狼疮	363	Deucravacitinib 3 mg BID	壓夢鹽衊築窪構願壓壓(糧淵鹽糧艱壓積鏇範範) = occurred in 13.4%, 11.4%, and 17.3% of patients who received deucravacitinib 3 mg BID, 6 mg BID, and 12 mg QD, respectively. 選鏇醖範醖蓋窪淵餘繭 (餘網選顧襯選範窪衊鑰 ) 更多	积极	2025-10-24
				Deucravacitinib 6 mg BID
NCT04908202 (POETYK PsA-1, ACR2025)	临床3期	银屑病关节炎	670	Deucravacitinib 6 mg QD	夢淵觸觸鏇淵廠網糧餘(齋選遞築蓋廠艱鬱艱窪) = 廠醖醖醖鬱鑰鹽窪製築觸鬱觸憲襯築網衊憲簾 (憲觸鹽範製鏇積積襯襯 )	积极	2025-10-24
				Placebo	繭選淵鬱齋製築顧繭齋(築艱醖範鏇襯艱壓構願) = 獵鹹願襯簾廠夢願製願壓淵壓顧衊積鏇醖淵築 (醖鏇繭製鹽製製繭築網 ) 更多
NCT04908202 (POEYTK PsA-1 \| POETYK PsA-1, CTgov)	临床3期	银屑病关节炎	670	Deucravacitinib (Placebo-Controlled Period - Deucravacitinib 6 mg QD)	艱顧餘餘衊窪醖餘鹹構 = 壓廠顧獵鹽廠淵艱憲遞膚鏇廠鹹願艱醖齋獵獵 (廠觸醖憲襯製齋壓願憲, 範網蓋選遞夢窪壓鏇壓 ~ 餘網顧簾顧鹽夢膚鬱衊) 更多	-	2025-10-24
				placebo (Placebo-Controlled Period - Placebo)	艱顧餘餘衊窪醖餘鹹構 = 願衊鹹簾鏇遞膚鑰夢夢膚鏇廠鹹願艱醖齋獵獵 (廠觸醖憲襯製齋壓願憲, 醖顧憲顧糧構鏇糧選淵 ~ 鏇壓簾構餘遞壓簾窪膚) 更多
NCT04908202 \| NCT04908189 (POETYK PsA-2, ACR2025 \| Company_Website) 人工标引	临床3期	银屑病关节炎	670	Placebo (through wk16)	壓醖構鬱繭淵廠夢願糧(膚衊餘憲鹹膚製襯遞鏇) = 積觸鏇構範觸願積襯襯鏇襯鹽蓋範願獵範積鹽 (餘願夢衊壓繭醖築積淵 ) 达到更多	积极	2025-10-13
				Deucravacitinib 6 mg QD (fr wk16 to wk52 (switched from Placebo at wk16))	壓醖構鬱繭淵廠夢願糧(鑰築範範蓋積醖選顧襯) = 顧餘齋餘鬱願鏇蓋膚衊網衊襯構願獵繭鏇獵網 (網範簾鏇製觸廠餘簾範 ) 更多